20172 - PH 2 Enfortumab in Urothelial Pts
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Disease Types: Bladder,&nbs
Available at: {clinical_trial_location backspace="7"}20172 - PH 2 Enfortumab in Urothelial Pts, {/clinical_trial_location}
Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}
{clinical_trial_description}